1 Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest 2010; 137: 318–325.
2 Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66: 699–708.
3 Yang M, Du Y, Chen H, Jiang D, Xu Z. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Int Immunopharmacol 2019; 77: 105950.
4 Harries TH, Seed PT, Jones S, Schofield P, White P. Chronic obstructive pulmonary disease hospital admissions and drugs--unexpected positive associations: a retrospective general practice cohort study. NPJ Prim Care Respir Med 2014; 24: 14006.
5 Jones RCM, Dickson-Spillmann M, Mather MJC, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 2008; 9: 62.
6 Jebrak G, Initiatives BPCO. [COPD routine management in France: are guidelines used in clinical practice?]. Rev Mal Respir 2010; 27: 11–18.
7 de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martín-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 2011; 189: 199–206.
8 Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. N Engl J Med 2014. doi:10.1056/NEJMoa1407154.
9 Rossi A, Guerriero M, Corrado A, OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014; 15: 77.
10 Gilworth G, Harries T, Corrigan C, Thomas M, White P. Perceptions of COPD patients of the proposed withdrawal of inhaled corticosteroids prescribed outside guidelines: A qualitative study. Chron Respir Dis 2019; 16: 1479973119855880.
11 Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019; 53. doi:10.1183/13993003.00164-2019.
12 Chalmers JD, Laska IF, Franssen FME, Janssens W, Pavord I, Rigau D et al. Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A European Respiratory Society Guideline. Eur Respir J 2020. doi:10.1183/13993003.00351-2020.
13 Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respir Res 2016; 3: e000151.
14 Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res 2020; 21: 3.
15 Pavord ID, Bafadhel M. Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk. J Allergy Clin Immunol 2013; 132: 828–829.
16 Toledo-Pons N, van Boven JFM, Román-Rodríguez M, Pérez N, Valera Felices JL, Soriano JB et al. ACO: Time to move from the description of different phenotypes to the treatable traits. PloS One 2019; 14: e0210915.
17 Cosio BG, Soriano JB, López-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de-Torres JP et al. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest 2016; 149: 45–52.
18 Hardin M, Cho M, McDonald M-L, Beaty T, Ramsdell J, Bhatt S et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014; 44: 341–350.
19 Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1773–1777.
20 Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N et al. Blood eosinophil levels as a biomarker in COPD. Respir Med 2018; 138: 21–31.
21 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
22 Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016; 355: i5239.
23 Harries TH, Gilworth G, Corrigan CJ, Murphy PB, Hart N, Thomas M et al. Inhaled Corticosteroids Prescribed for COPD Patients with Mild or Moderate Airflow Limitation: Who Warrants a Trial of Withdrawal? Int J Chron Obstruct Pulmon Dis 2019; 14: 3063–3066.
24 White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with Inhaled Corticosteroids - Implications for Safety and Costs: Cross-Sectional Observational Study. PloS One 2013; 8: e75221.
25 Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol 2017; 17: 99–103.
26 Horak F, Doberer D, Eber E, Horak E, Pohl W, Riedler J et al. Diagnosis and management of asthma – Statement on the 2015 GINA Guidelines. Wien Klin Wochenschr 2016; 128: 541–554.
27 Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138.
28 Tzortziou Brown V, Patel I, Thomas N, Tomlinson J, Roberts R, Rayner H et al. New ways of working; delivering better care for people with long-term conditions. Lond J Prim Care 2017; 9: 60–68.
29 Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–796.
30 Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200: e70–e88.
31 Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648–654.
32 Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250–255.
33 Houben-Wilke S, Janssen DJA, Franssen FME, Vanfleteren LEGW, Wouters EFM, Spruit MA. Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores. Health Qual Life Outcomes 2018; 16: 205.
34 Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2: 195–203.
35 Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease. J Cardiopulm Rehabil Prev 2019; 39: E6–E11.
36 Çolak Y, Afzal S, Nordestgaard BG, Marott JL, Lange P. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study. Eur Respir J 2018; 52. doi:10.1183/13993003.00616-2018.
37 Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602–615.
38 Harries TH, White P. Spotlight on primary care management of COPD: Electronic health records. Chron Respir Dis 2021; 18: 1479973120985594.
39 Global Initiative for Asthma. Global Initiative for Asthma. Global strategy for asthma management and prevention (2021 update). ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf.
40 Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma Off J Assoc Care Asthma 2005; 42: 367–372.
41 Yadollahzadeh M, Hashemian SM, Kiani A, Ghorbani F, Najafizadeh K, Razavi F et al. Diagnostic values of bronchodilator response versus 9-question questionnaire for asthma. Adv Respir Med 2019; 87: 269–275.
42 Corrigan CJ. Calcilytics: a non-steroidal replacement for inhaled steroid and SABA/LABA therapy of human asthma? Expert Rev Respir Med 2020; : 1–10.
43 Baron AJ, Blok BMF, Heijst E van, Riemersma RA, Voort AMS der, Metting EI et al.<p>Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/COPD Service for Primary Care</p>. Int. J. Chron. Obstruct. Pulmon. Dis. 2020; 15: 1601–1611.
44 Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659–664.
45 Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–750.
46 Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012; 67: 701–708.